Tough business climate roils IMS

Share this article:

IMS Health said it intends to lay off 10% of its workforce, or as many as 760 employees worldwide. The firm will take a 2007 Q4 charge of $86-$90 million to account for the terminations.

To be completed by year's end, IMS said the layoffs are designed to help survive a tough business climate. Last year many of its potential clients announced layoffs, including Pfizer, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Amgen. Meanwhile, IMS saw moderating revenue growth and pressure on operating margins.

In an SEC filing, IMS said its restructuring would impact 1,050 employees. (The firm may add back some new positions in higher growth markets.) Those who do statistical and analytical work, as well as consultants, will be affected, as well as marketing, finance and administration.

IMS, which operates in more than 100 countries with about 7,600 employees worldwide, had 2006 revenue of $2 billion. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?